| ncRNA name | ANRIL |
| ncRNA Category | lncRNA |
| ID | 100048912 |
| Ensembl | ENSG00000240498 |
| Synonyms | CDKN2B-AS1, CDKN2B-AS, CDKN2BAS, NCRNA00089, PCAT12, RP11-145E5.4, p15AS |
| Disease name | retinoblastoma (RB) |
| Species | Homo sapiens |
| Tissues/Cell_line | RB samples and adjacent noncancerous tissues; RB cell lines Y79, HXO-RB44 and SO-RB50; RPE cell line ARPE-19 |
| Methods | qRT-PCR, transfection, CCK-8 assay, transwell assay, luciferase reporter assay, Western blot |
| Expression pattern | up-regulated |
| Functional description | Overexpression of ANRIL promoted viability, migration and invasion of retinoblastoma cells by activating MEK/ERK and Wnt/β-catenin pathways, as well as down-regulating miR-24 and then up-regulating c-Myc. |
| PubMed ID | 30703428 |
| Year | 2019 |
| Title | ANRIL acts as onco-lncRNA by regulation of microRNA-24/c-Myc, MEK/ERK and Wnt/β-catenin pathway in retinoblastoma. |
| Drug-related ncRNA | NO |
Copyright © Institution of Biomedical Big Data, Wenzhou Medical University All rights reserved.